|
Learn about the common usage, side effects and recommended Dosage of Generic Co-Aprovel
Common usage of Generic for Co-Aprovel
Generic Co-Aprovel is an anti hypertensive used to treat high blood pressure. Irbesartan (Generic Co-Aprovel) works by lowering blood pressure by preventing a strong chemical in the body from increasing blood pressure.
Probable Side Effects of Generic for Co-Aprovel
Like most medications, Generic Co-Aprovel can cause some temporary side effects. It is pertinent to note that Generic Co-Aprovel side effects cannot be anticipated. If they continue it is imperative that you contact your doctor immediately. The most common Side Effects of Generic Co-Aprovel are depression, nightmares, diarrhea, dry eyes or dry mouth, headache and increased sensitivity to the sun. Some of the most serious Generic Co-Aprovel side Effects include changes in vision, cold, tingling, or numb hands or feet, confusion, dizziness, lightheadedness or fainting spells and difficulty breathing, wheezing. This is not a complete list of all Side effects. Do concur with your doctor and follow his directions completely when you are taking Generic Co-Aprovel
Recommended Dosage of Generic for Co-Aprovel
The following information just highlights the general average dosage of Generic Co-Aprovel
Adults
The recommended initial dose of Irbesartan (Generic Co-Aprovel) is 150 mg once daily. Patients requiring further reduction in blood pressure should be titrated to 300 mg once daily.
IMPORTANT NOTE
Any medication should be taken with the prior counsel and direction of your health care provider. It is important to discuss Generic Co-Aprovel dosage and Generic Co-Aprovel Side effects with your doctor. Certain basic lifestyle changes, moderation or abstinence in the case of alcoholic beverages and a regular exercise regimen will go a long way in improving your quality of life. This website Drug Information is to be solely used as an information resource and should never be used to replace contact with your licensed health care provider. |
